Overview
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
Status:
Completed
Completed
Trial end date:
2004-05-01
2004-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the relationship between viral suppression and changes in immune function, as measured by the restoration of delayed-type hypersensitivity (DTH) and lymphoproliferative (LP) responses, observed after 48 weeks of treatment with highly active antiretroviral therapy (HAART) in ACTG 315. To evaluate the durability of the antiviral and immunologic effects of long-term treatment with HAART. Given the extensive immunologic and virologic data available from ACTG 315, follow-up studies of this advanced-disease population are indicated to primarily ascertain the impact of long-term suppression of viral replication on immunologic reconstitution or re-education and the durability of the antiviral effects of HAART.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)Treatments:
Delavirdine
Didanosine
Lamivudine
Ritonavir
Saquinavir
Stavudine
Zidovudine
Criteria
Inclusion CriteriaConcurrent Medication:
Allowed:
- Protocol Chair-approved antiretroviral medications or research study treatment for an
HIV complication.
- Treatment, maintenance, or chemoprophylaxis with approved medications for
opportunistic infections.
- Antibiotics.
- Recombinant erythropoietin (rEPO) and granulocyte colony-stimulating factor (G-CSF,
filgrastim).
- Regularly prescribed medications, such as antipyretics, analgesics, allergy
medications, antidepressants, sleep medications, oral contraceptives (not as a sole
form of birth control), megestrol acetate, testosterone, or any other medication not
explicitly excluded.
- Alternative therapies such as vitamins, acupuncture, and visualization techniques.
Patients must have:
- HIV-positive status.
- Completion of 48 weeks of study treatment in ACTG 315 and maintenance in this regimen
(on-study) until enrollment in this study.
- Signed, informed consent from parent or legal guardian for patients less than 18 years
of age.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions and symptoms are excluded:
- Documented or suspected pancreatitis or hepatitis within 2 weeks prior to study entry.
Concurrent Medication:
Excluded:
- Immunomodulators that affect immunologic or virologic indices (e.g., systemic
corticosteroids, thalidomide, cytokines).
- Ketoconazole, rifampin, and rifabutin.
- Amiodarone, astemizole, bepridil, bupropion, cisapride, clozapine, dihydroergotamine,
encainide, ergotamine, flecainide, meperidine, pimozide, piroxicam, propafenone,
propoxyphene, quinidine, terfenadine, alprazolam, clorazepate, diazepam, estazolam,
flurazepam, midazolam, triazolam, zolpidem, phenytoin, phenobarbital, and
carbamazepine.
[AS PER AMENDMENT 3/5/01:
- Lovastatin and simvastatin.
Excluded for patients who are pregnant:
- ddI or d4T.]
Avoided:
- Herbal medications.
[2. AS PER AMENDMENT 4/10/00:
- Use of ddI is contraindicated in patients who have serum amylase or lipase values over
1.5 times the ULN (Upper Limit of Normal), fasting triglycerides of 100 mg/dl or more,
or a history of pancreatitis. Use ddI with extreme caution and only if clinically
indicated in patients with known risk factors. Refer to package insert for more
information.]
Concurrent Treatment:
Excluded:
- Systemic cytotoxic chemotherapy.
Prior Medication:
Excluded:
- Any antiretroviral medications other than the zidovudine, lamivudine, and ritonavir
supplied in ACTG 315 or alternative antiretrovirals not approved by protocol chairs,
48 weeks prior to study entry.
- Immunomodulatory therapies within 30 days prior to study entry.
Required:
Zidovudine (200 mg tid or 300 mg bid) plus lamivudine (150 mg bid) plus ritonavir (500 or
600 mg bid, or 300 mg tid) for 48 weeks in ACTG 315.
Active substance or alcohol abuse or dependence that would interfere with adherence to
study requirements.